EA201491276A1 - Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2 - Google Patents
Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2Info
- Publication number
- EA201491276A1 EA201491276A1 EA201491276A EA201491276A EA201491276A1 EA 201491276 A1 EA201491276 A1 EA 201491276A1 EA 201491276 A EA201491276 A EA 201491276A EA 201491276 A EA201491276 A EA 201491276A EA 201491276 A1 EA201491276 A1 EA 201491276A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- benzilsulphonamide
- mogat
- inhibitors
- new
- derivatives suitable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261592717P | 2012-01-31 | 2012-01-31 | |
EP12382432 | 2012-11-06 | ||
PCT/US2013/022870 WO2013116075A1 (en) | 2012-01-31 | 2013-01-24 | Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201491276A1 true EA201491276A1 (ru) | 2014-10-30 |
Family
ID=47148691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201491276A EA201491276A1 (ru) | 2012-01-31 | 2013-01-24 | Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2 |
Country Status (27)
Country | Link |
---|---|
US (1) | US8575352B2 (pt) |
EP (1) | EP2809651B1 (pt) |
JP (1) | JP2015511232A (pt) |
KR (1) | KR20140106750A (pt) |
CN (1) | CN104066719B (pt) |
AP (1) | AP2014007794A0 (pt) |
AR (1) | AR089771A1 (pt) |
AU (1) | AU2013215468A1 (pt) |
BR (1) | BR112014018636A8 (pt) |
CA (1) | CA2859995A1 (pt) |
CL (1) | CL2014001861A1 (pt) |
CO (1) | CO7010839A2 (pt) |
CR (1) | CR20140322A (pt) |
DO (1) | DOP2014000178A (pt) |
EA (1) | EA201491276A1 (pt) |
ES (1) | ES2590929T3 (pt) |
GT (1) | GT201400167A (pt) |
HK (1) | HK1199025A1 (pt) |
IL (1) | IL233712A0 (pt) |
MA (1) | MA35886B1 (pt) |
MX (1) | MX2014008599A (pt) |
PE (1) | PE20141679A1 (pt) |
PH (1) | PH12014501711A1 (pt) |
SG (1) | SG11201404106QA (pt) |
TW (1) | TW201343629A (pt) |
WO (1) | WO2013116075A1 (pt) |
ZA (1) | ZA201404836B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013112323A1 (en) | 2012-01-23 | 2013-08-01 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors |
ES2571577T3 (es) | 2012-01-31 | 2016-05-26 | Lilly Co Eli | Derivados novedosos de morfolinilo útiles como inhibidores de MOGAT-2 |
AU2013341584A1 (en) | 2012-11-06 | 2015-04-30 | Eli Lilly And Company | Novel benzyl sulfonamide compounds useful as MoGAT-2 inhibitors |
US10934244B2 (en) | 2015-06-15 | 2021-03-02 | Nmd Pharma A/S | Compounds for use in treating neuromuscular disorders |
TWI782056B (zh) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有mgat2抑制活性的縮合環衍生物 |
US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
KR20210114001A (ko) | 2019-01-11 | 2021-09-17 | 시오노기 앤드 컴파니, 리미티드 | Mgat2 저해 활성을 갖는 다이하이드로피라졸로피라지논 유도체 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1659113A1 (en) * | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
EP1655283A1 (en) * | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
AU2005303492A1 (en) * | 2004-11-10 | 2006-05-18 | Pfizer Inc. | Substituted N-sulfonylaminobenzyl-2-phenoxy acetamide compounds |
CN101087771A (zh) * | 2004-11-10 | 2007-12-12 | 辉瑞大药厂 | 经取代n-磺酰基氨基苄基-2-苯氧基乙酰胺化合物 |
AU2007297285A1 (en) * | 2006-09-08 | 2008-03-20 | Pfizer Products Inc. | Diaryl ether derivatives and uses thereof |
EP2078719A4 (en) | 2006-09-28 | 2009-11-11 | Dainippon Sumitomo Pharma Co | COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION |
CA2669311C (en) * | 2006-11-13 | 2011-09-20 | Pfizer Products Inc. | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |
WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
CA2751244A1 (en) | 2009-02-23 | 2010-08-26 | Msd K.K. | Pyrimidin-4(3h)-one derivatives |
WO2013112323A1 (en) | 2012-01-23 | 2013-08-01 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors |
ES2571577T3 (es) | 2012-01-31 | 2016-05-26 | Lilly Co Eli | Derivados novedosos de morfolinilo útiles como inhibidores de MOGAT-2 |
-
2013
- 2013-01-21 TW TW102102260A patent/TW201343629A/zh unknown
- 2013-01-21 AR ARP130100180A patent/AR089771A1/es unknown
- 2013-01-24 US US13/748,627 patent/US8575352B2/en not_active Expired - Fee Related
- 2013-01-24 CA CA2859995A patent/CA2859995A1/en not_active Abandoned
- 2013-01-24 AP AP2014007794A patent/AP2014007794A0/xx unknown
- 2013-01-24 MX MX2014008599A patent/MX2014008599A/es unknown
- 2013-01-24 BR BR112014018636A patent/BR112014018636A8/pt not_active IP Right Cessation
- 2013-01-24 PE PE2014001197A patent/PE20141679A1/es not_active Application Discontinuation
- 2013-01-24 CN CN201380007085.XA patent/CN104066719B/zh active Active
- 2013-01-24 ES ES13703234.8T patent/ES2590929T3/es active Active
- 2013-01-24 AU AU2013215468A patent/AU2013215468A1/en not_active Abandoned
- 2013-01-24 EA EA201491276A patent/EA201491276A1/ru unknown
- 2013-01-24 SG SG11201404106QA patent/SG11201404106QA/en unknown
- 2013-01-24 EP EP13703234.8A patent/EP2809651B1/en active Active
- 2013-01-24 JP JP2014555589A patent/JP2015511232A/ja not_active Ceased
- 2013-01-24 KR KR1020147021127A patent/KR20140106750A/ko not_active Application Discontinuation
- 2013-01-24 WO PCT/US2013/022870 patent/WO2013116075A1/en active Application Filing
-
2014
- 2014-06-30 ZA ZA2014/04836A patent/ZA201404836B/en unknown
- 2014-07-04 CR CR20140322A patent/CR20140322A/es unknown
- 2014-07-15 CL CL2014001861A patent/CL2014001861A1/es unknown
- 2014-07-17 IL IL233712A patent/IL233712A0/en unknown
- 2014-07-24 CO CO14161422A patent/CO7010839A2/es unknown
- 2014-07-24 MA MA37244A patent/MA35886B1/fr unknown
- 2014-07-29 GT GT201400167A patent/GT201400167A/es unknown
- 2014-07-30 PH PH12014501711A patent/PH12014501711A1/en unknown
- 2014-07-30 DO DO2014000178A patent/DOP2014000178A/es unknown
- 2014-12-11 HK HK14112466.4A patent/HK1199025A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DOP2014000178A (es) | 2014-08-31 |
AR089771A1 (es) | 2014-09-17 |
AU2013215468A1 (en) | 2014-07-10 |
HK1199025A1 (en) | 2015-06-19 |
CL2014001861A1 (es) | 2014-11-07 |
GT201400167A (es) | 2015-05-28 |
BR112014018636A8 (pt) | 2017-07-11 |
US8575352B2 (en) | 2013-11-05 |
AP2014007794A0 (en) | 2014-07-31 |
BR112014018636A2 (pt) | 2017-06-20 |
CN104066719B (zh) | 2016-08-24 |
MX2014008599A (es) | 2014-08-22 |
CO7010839A2 (es) | 2014-07-31 |
EP2809651B1 (en) | 2016-06-29 |
SG11201404106QA (en) | 2014-08-28 |
ES2590929T3 (es) | 2016-11-24 |
MA35886B1 (fr) | 2014-12-01 |
CR20140322A (es) | 2014-08-25 |
CN104066719A (zh) | 2014-09-24 |
US20130197039A1 (en) | 2013-08-01 |
ZA201404836B (en) | 2017-08-30 |
KR20140106750A (ko) | 2014-09-03 |
EP2809651A1 (en) | 2014-12-10 |
WO2013116075A1 (en) | 2013-08-08 |
PH12014501711A1 (en) | 2014-10-13 |
TW201343629A (zh) | 2013-11-01 |
JP2015511232A (ja) | 2015-04-16 |
PE20141679A1 (es) | 2014-11-08 |
CA2859995A1 (en) | 2013-08-08 |
IL233712A0 (en) | 2014-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201491276A1 (ru) | Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2 | |
CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
EA201792535A1 (ru) | Гетероциклические амиды в качестве ингибиторов киназ | |
EA201591455A1 (ru) | Производные бензимидазолона в качестве ингибиторов бромодомена | |
EA201691085A1 (ru) | Замещенные бензамиды и способы их применения | |
EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
EA201790407A1 (ru) | Зонды для визуализации белка хантингтина | |
EA201401292A3 (ru) | Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их | |
EA201690952A1 (ru) | Пиразол для лечения аутоиммунных расстройств | |
EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
EA201490474A1 (ru) | Аминохиназолины в качестве ингибиторов киназ | |
EA201890331A1 (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
EA201690764A1 (ru) | Ингибитор грелин-o-ацилтрансферазы | |
EA201591360A1 (ru) | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств | |
EA201690844A1 (ru) | Ингибиторы gsk-3 | |
EA201592183A1 (ru) | Ингибиторы bace | |
EA201590552A1 (ru) | Аминохинолины в качестве ингибиторов киназы | |
EA201790400A1 (ru) | Зонды для визуализации белка хантингтина | |
DOP2014000177A (es) | Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2 | |
EA201690523A1 (ru) | Триазолопиридины, композиции и способы их применения | |
EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз |